6 completed, 4 unknown, 3 terminated, 3 withdrawn. 11 Phase 2, 9 Phase 1, 5 Phase 3.
Follow Squamous Non-small Cell Lung Cancer: new trials by email Literature Review of Squamous Non-small Cell Lung Cancer trials Research Report on Squamous Non-small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer Carboplatin Injection, Paclitaxel Injection - Squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 480 | 2026-01-15 | 2026-01-22 |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) Intismeran Autogene, Pembrolizumab, Carboplatin - Squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 180 | 2025-12-12 | 2026-10-01 |
| Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS pembrolizumab, valemetostat - Sinonasal Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-07-09 | 2025-07-10 | |
| Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin" - Squamous Non-small Cell Lung Cancer | Phase 2 | Unknown | Qilu Hospital of Shandong University | 46 | 2021-12-03 | 2022-02-17 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 460 | 2021-10-18 | 2026-10-13 |
| A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung Second line (2L) afatinib, Second line chemotherapy - Squamous Non-small Cell Lung Cancer | Completed | Boehringer Ingelheim | 200 | 2020-05-08 | 2022-01-11 | |
| Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer Anlotinib, Placebos, Paclitaxel - Squamous Non-small Cell Lung Cancer | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 386 | 2019-10-31 | 2019-08-29 |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies CPL304110 - Gastric Cancer, Bladder Cancer | Phase 1 | Unknown | Celon Pharma SA | 42 | 2019-07-19 | 2024-02-07 |
| Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Durvalumab, Tremelimumab - Squamous Non-small Cell Lung Cancer, Non-Squamous Non-small Cell Lung Cancer | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2018-11-01 | 2022-01-10 | |
| Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC Avelumab, Cetuximab, Gemcitabine - Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 43 | 2018-10-30 | 2022-06-06 |
| Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) Nivolumab 10 MG/ML Intravenous Solution, Best Supportive Care - Squamous Non-small Cell Lung Cancer | Phase 3 | Unknown | Gruppo Oncologico Italiano di Ricerca Clinica | 125 | 2017-09-25 | 2022-10-03 |
| A Study to Assess the Efficacy and Safety of ABTL0812 ABTL0812 in combination with paclitaxel and carboplatin - Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Ability Pharmaceuticals SL | 103 | 2016-12-01 | 2023-02-22 |
| Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Sym004, Nivolumab - Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Symphogen A/S | 2016-11-01 | 2017-08-28 | |
| A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody, Carboplatin, Nab-Paclitaxel - Squamous Non-Small Cell Lung Cancer | Phase 3 | Completed | Hoffmann-La Roche | 1021 | 2015-06-11 | 2022-03-21 |
| A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology Carboplatin, Paclitaxel, RO5479599 - Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 12 | 2014-10-01 | 2017-01-25 |
| Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Carboplatin, Veliparib, Paclitaxel - Squamous Non-Small Cell Lung Cancer | Phase 3 | Completed | AbbVie | 970 | 2014-04-10 | 2020-11-17 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Lucitanib - Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 18 | 2014-04-01 | 2019-07-29 |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Buparlisib, Buparlisib matching placebo, Docetaxel - Squamous Non-small Cell Lung Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 27 | 2013-10-01 | 2018-08-14 |
| A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Necitumumab, Gemcitabine, Cisplatin - Squamous Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 192 | 2013-05-07 | 2019-10-25 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (4) · Endometrial Neoplasms (3) · Lung Neoplasms (3) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms by Site (9) · Neoplasms (8) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Lung Neoplasms (3) · Neoplasms by Histologic Type (3)
Carboplatin (8) · Paclitaxel (7) · Nivolumab (3) · pembrolizumab (3) · 130-nm albumin-bound paclitaxel (2) · Cisplatin (2) · Gemcitabine (2) · ABTL0812 (1) · AZD5305 (1) · Afatinib (1) · Antibodies (1) · Cetuximab (1) · Docetaxel (1) · Drug Therapy (1) · E-3810 (1)
Hoffmann-La Roche (2) · AbbVie (1) · Ability Pharmaceuticals SL (1) · AstraZeneca (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Celon Pharma SA (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Clovis Oncology, Inc. (1) · Eli Lilly and Company (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Merck KGaA, Darmstadt, Germany (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1)
Spain (9) · United States (9) · Italy (7) · Canada (5) · France (5) · Australia (4) · China (4) · Germany (4) · Poland (4) · Belgium (3) · Brazil (3) · Hungary (3) · Japan (3) · Netherlands (3) · South Korea (3)
Ana Oaknin (1) · Andrea Ardizzoni, Dr (1) · Jared Weiss, MD (1) · Lizza Hendriks, MD (1) · Marcello Tiseo, Dr (1) · Martin Reck, Pr (1) · Vassiliki Saloura, M.D. (1)
PMID 30797492, PMID 33199155, PMID 34436928, PMID 35293148, PMID 35511917, PMID 35844029, PMID 36718142, PMID 39039449, PMID 39392424, PMID 39485534, PMID 39700681
2014 (2), 2016 (1), 2017 (1), 2018 (1), 2025 (1)